Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI) is a biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company specializes in advancing innovative treatments, including vaccines designed to stimulate the immune system against specific tumor-associated antigens. Its pipeline primarily targets breast and other solid tumors.
Company News
Greenwich LifeSciences expanded its Phase III clinical trial FLAMINGO-01 to Belgium, adding the country to its existing European trial sites. The trial evaluates GLSI-100, an immunotherapy to prevent breast cancer recurrences, with Dr. Patrick Neven serving as the national principal investigator.
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator ...
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?